Summary:
- The article discusses the research efforts of Immutep, a biotechnology company, into developing treatments for cancer and autoimmune diseases.
- Immutep is focusing on developing immunotherapies that target the LAG-3 protein, which plays a role in regulating the immune system and has been identified as a potential target for cancer and autoimmune disease treatments.
- The article highlights Immutep's ongoing clinical trials for its lead candidate, eftilagimod alpha, which is being evaluated for the treatment of various solid tumors and autoimmune conditions, such as ulcerative colitis and rheumatoid arthritis.